Literature DB >> 15952923

Use of medications in Wolff-Parkinson-White syndrome.

D P Redfearn1, A D Krahn, A C Skanes, R Yee, G J Klein.   

Abstract

The diagnosis of Wolff-Parkinson-White syndrome is generally straightforward; however, the management may not be, and requires an understanding of the competing risks of various treatment options and that of the clinical setting in which the diagnosis is made. The symptomatic patient with Wolff-Parkinson-White has an increased risk of atrial fibrillation and a small but significant risk of sudden cardiac death. Therapy is based on reduction in symptom burden and attenuation of the risk of pre-excited atrial fibrillation. Catheter ablation is the most effective means of achieving this goal with abolition of symptoms and risk of pre-excited atrial fibrillation. Medication is often employed in the acute setting to terminate paroxysms of arrhythmia associated with the accessory pathway and reduce the subsequent burden of symptoms until ablation can be performed. An overview of the agents commonly used is provided together with recommendations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15952923     DOI: 10.1517/14656566.6.6.955

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  2 in total

Review 1.  Diagnosis and management of supraventricular tachycardias.

Authors:  Lior Bibas; Michael Levi; Vidal Essebag
Journal:  CMAJ       Date:  2016-10-24       Impact factor: 8.262

2.  A case report of a patient with wide complex tachycardia due to Wolff-Parkinson-White syndrome mimicking ventricular tachycardia.

Authors:  Stefan Preisendörfer; Gabriele Hessling; Isabel Deisenhofer; Felix Bourier
Journal:  Eur Heart J Case Rep       Date:  2021-09-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.